Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Bonus Article Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostSubmitted by Chris Markoch. Publication Date: 2/5/2026. 
What You Need to Know - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average (DJIA) after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer posted adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study of its lead GLP-1 candidate. Wall Street Journal best-selling author James Altucher has uncovered a way to get a pre-IPO stake BEFORE Starlink goes public.
All it takes is just a few minutes of time and as little as $100 to get started. Plus, you can take action right inside your regular brokerage account. Click here now to see how to take action. PFE stock closed up about 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. One forecast projects the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate (CAGR) of about 9.7%. For Pfizer, that opportunity centers on its lead GLP-1 candidate, MET-097i. The company reported results from its Phase 2b VESPER-3 study, which met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued losing weight after switching from weekly to monthly dosing, with no plateau observed by week 28. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom pointed to the positive clinical trial results as the reason for the stock's gain. That may be true, but that kind of reaction can be a short-lived sugar high. While Pfizer's GLP-1 candidate shows promise, it will take time for that to translate into material revenue. The GLP-1 trade is also becoming more crowded, and incumbents like Eli Lilly & Co. (NYSE: LLY) are unlikely to cede market leadership quickly. There are other reasons to be bullish on PFE, notably its oncology portfolio. Industry data from Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026, projected to rise to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had about 60 candidates in its pipeline, representing multiple opportunities to capture market share. The portfolio was substantially strengthened after its acquisition of Seagen in 2023. Pfizer's late-stage roster includes Vepdegestrant, a next-gen targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, both aimed at ER+/HER2- metastatic breast cancer. Other late-stage candidates include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) against metastatic non-small cell lung cancer, leveraging Seagen-acquired ADC expertise.
- Sasanlimab, being evaluated for bladder cancer, and PF-4404, a bispecific PD-1xVEGF agent being studied in combination with Padcev to treat urothelial cancer — programs positioned for potential blockbuster outcomes amid oncology growth.
Beyond the pipeline, Pfizer's commitment to artificial intelligence (AI) is another differentiator in the broader biopharmaceutical sector. Pfizer uses AI across R&D through partnerships with firms like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology analytics. These tools and platforms — including OncoScout for target identification — have helped speed parts of discovery by significant margins. Internally, platforms such as "Charlie" handle data mining, predictions and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) optimize discovery and manufacturing workflows. These efforts helped accelerate the development of Paxlovid and underpin planned 2026 catalysts in oncology and obesity. Pfizer is also targeting $1.2 billion in savings by 2027 through efficiency gains driven by AI. Industry-wide, AI is expected to boost productivity by roughly 35% to 45% by improving preclinical decisions and trial design, making it a core competitive edge rather than optional hype. Pfizer's early and broad adoption of these technologies should be a tailwind for investors over the medium and long term.
| 
